Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

ardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... Company, Inc. (NYSE: LCI ) today announced that ... facility to $120 million from $50 million.  The amended ... company to increase borrowings by a total of up ... commitments from existing lenders or new lending institutions.  The ... 2018.   "The amended credit facility, together ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/24/2015)... (PRWEB) April 24, 2015 The 1975 ... toured almost constantly across the globe to theaters, festivals and ... in Manchester, they’ve partnered with their label, Dirty Hit Records, ... Teaming up with the newly launched Cadence & Cause ... their debut LP on vinyl and a signed photo card. ...
(Date:4/24/2015)... April 24, 2015 Lowcostcarinsuranceprice.com has released ... low cost auto insurance for senior citizens . ... but this does not mean that they cannot find ... senior drivers can find the right coverage for their ... brokerage website like http://lowcostcarinsuranceprice.com/ provides free leads ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new supplements focused ... A unique combination of herbs and nutrients, including ... apart from other antioxidant supplements. This formula relies ... versus the use of single or sequential compounds ... Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with Setria® Glutathione. ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... 2015 IntelliSoft Group, LLC, a ... contract management software, featured IntelliCred Version 14.2 during ... Annual Educational Conference (IAMSS) on April 23-24 ... Brook, Illinois. , Notable improvements available in IntelliSoft’s ... , Contract Linking: A new Contract Connection ...
Breaking Medicine News(10 mins):Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Low Cost Auto Insurance Quotes for Senior Citizens 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:IntelliSoft Group Version 14.2 of IntelliCred featured at the Illinois Association of Medical Staff Services Annual Educational Conference 2
... ... American Society of Pain Educators to pursue publishing and teaching opportunities. , ... (PRWEB) April 16, 2010 -- ... education and producers of PAINWeek ( www.painweek.org ) — the national conference ...
... ... take advantage of the Home Buyer Tax Credit before April 30th by having 100 new homes ... tours on their newly redesigned website allows potential home buyers to save time while they seek ... ...
... A class of brain tumor that tends to emerge in ... identified by examining DNA methylation of a specific set of ... Cancer Center and colleagues with The Cancer Genome Atlas report ... national research group discovered that hypermethylation is a defining aspect ...
... Study found boys went for cars and trucks, while girls chose ... may want their girls to grow up to be astronauts and ... care and housework duties, but a new study suggests certain stereotypical ... When presented with seven different toys, boys as young as 9 ...
... find , THURSDAY, April 15 (HealthDay News) -- Many people ... aware of it or don,t seek medical treatment for more ... researchers analyzed data from 1,000 patients, average age 73, who ... A TIA -- often called by the misnomer "mini-stroke" ...
... from yeast to rodents to humans all benefit from cutting ... even triple lifespan. It,s not yet clear just how much ... practice the strict diet hope to survive past 100 years ... edition of Science , nutrition and longevity researchers at ...
Cached Medicine News:Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 2Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 3Health News:Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase 2Health News:Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase 3Health News:Molecular discovery points to new therapies for brain tumors 2Health News:Molecular discovery points to new therapies for brain tumors 3Health News:Even 9-Month-Olds Choose 'Gender-Specific' Toys 2Health News:Even 9-Month-Olds Choose 'Gender-Specific' Toys 3Health News:Most People Unaware They've Had a Minor Stroke 2Health News:Perhaps a longer lifespan, certainly a longer 'health span' 2Health News:Perhaps a longer lifespan, certainly a longer 'health span' 3
... have proven that the management of diabetes in ... levels is the most effective way to reduce ... aimed at maintaining or improving a diabetes patients ... costly. , ,These have been the guiding ...
... about insulin dosages and other medication, about ... by data from blood glucose tests and ... that can be seen by you and ... is presented in organized and graphical formats. ...
... Green Photocoagulator - Portable and rugged solid-state ... clinic, and operating room. Built to high-duty ... the most demanding environments, the Novus Verdi ... A full line of accessories for private ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Medicine Products: